Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin

Pharmacogenomics

Volumn 12, Issue 1, 2011, Pages 27-39

  Gordon, Michael A ^a   Zhang, Wu ^a   Yang, Dongyun ^b   Iqbal, Syma ^a   El Khouiery, Anthony ^a   Nagashima, Fumio ^a   Lurje, Georg ^a   Labonte, Melissa ^b   Wilson, Peter ^b   Sherrod, Andy ^b   Ladner, Robert D ^b   Lenz, Heinz Josef ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

colorectal cancer; estrogen receptor b; gender; oxaliplatin; polymorphism

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR BETA; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PHOSPHOLIPASE A2; VOLTAGE GATED SODIUM CHANNEL; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG RESPONSE; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOME ANALYSIS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTION; PROGRESSION FREE SURVIVAL; RACE DIFFERENCE; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SEX CHARACTERISTICS;

EID: 78650425294     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.163     Document Type: Article

References (64)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics. CA Cancer J. Clin. 59(4), 225-249 (2009).
2. Nguyen H, Tran A, Lipkin S, Fruehauf JP: Pharmacogenomics of colorectal cancer prevention and treatment. Cancer Invest. 24(6), 630-639 (2006).
3. Pohl A, Lurje G, Manegold PC, Lenz HJ: Pharmacogenomics and -genetics in colorectal cancer. Adv. Drug Deliv. Rev. 61(5), 375-380 (2009).
4. Pullarkat ST, Stoehlmacher J, Ghaderi V et al.: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1(1), 65-70 (2001).
5. Stoehlmacher J, Park DJ, Zhang W et al.: A multivariate ana lysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br. J. Cancer 91(2), 344-354 (2004).
6. Wilson PM, Ladner RD, Lenz HJ: Predictive and prognostic markers in colorectal cancer. Gastrointest. Cancer Res. 1(6), 237-246 (2007).
7. Carreras C W, Santi DV: The catalytic mechanism and structure of thymidylate synthase. Annu. Rev. Biochem. 64, 721-762 (1995).
8. Karlberg M, Ohrling K, Edler D, Hallstrom M, Ullen H, Ragnhammar P: Prognostic and predictive value of thymidylate synthase expression in primary colorectal cancer. Anticancer Res. 30(2), 645-651 (2010).
9. Rosenblatt DS: Methylenetetrahydrofolate reductase. Clin. Invest. Med. 24(1), 56-59 (2001).
10. Zhang W, Press OA, Haiman CA et al.: Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specifc survival in patients with metastatic colon cancer. J. Clin. Oncol. 25(24), 3726-3731 (2007).
11. Earley JN, Turchi J: Interrogation of nucleotide excision repair capacity: impact on platinum-based cancer therapy. Antioxid. Redox Signal (2010) (Epub ahead of print).
12. Seetharam RN, Sood A, Basu-Mallick A, Augenlicht LH, Mariadason JM, Goel S: Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells. Anticancer Res. 30(7), 2531-2538 (2010).
13. Le Morvan V, Smith D, Laurand A et al.: Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 8(12), 1693-1703 (2007).
14. Kim SH, Kwon HC, Oh SY et al.: Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am. J. Clin. Oncol. 32(1), 38-43 (2009).
15. Fraser SP, Diss JK, Chioni AM et al.: Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin. Cancer Res. 11(15), 5381-5389 (2005).
16. Grimes JA, Fraser SP, Stephens GJ et al.: Differential expression of voltage-activated Na+ currents in two prostatic tumour cell lines: contribution to invasiveness in vitro. FEBS Lett. 369(2-3), 290-294 (1995).
17. Laniado ME, Lalani EN, Fraser SP et al.: Expression and functional ana lysis of voltage-activated Na+ channels in human prostate cancer cell lines and their contribution to invasion in vitro. Am. J. Pathol. 150(4), 1213-1221 (1997).
18. Provides a functional link between sodium channels and cancer progresion. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J. Neurophysiol. 85(5), 2293-2297 (2001).
19. + channel function in vivo. Clin. Cancer Res. 12(15), 4481-4484 (2006).
20. Jun L, Haiping Z, Beibei Y: Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients. Swiss. Med. Wkly 139(49-50), 724-728 (2009).
21. Dang DT, Chen F, Kohli M, Rago C, Cummins JM, Dang LH: Glutathione S-transferase P1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Res. 65(20), 9485-9494 (2005).
22. Naidu KA, Nasir A, Pinkas H, Kaiser HE, Brady P, Coppola D: Glutathione-S-transferase P1 expression and activity is increased in colonic neoplasia. In vivo 17(5), 479-482 (2003).
23. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107(4), 1183-1188 (1994).
24. Waugh DJ, Wilson C: The interleukin-8 pathway in cancer. Clin. Cancer Res. 14(21), 6735-6741 (2008).
25. Wente MN, Keane MP, Burdick MD et al.: Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett. 241(2), 221-227 (2006).
26. Heidemann J, Ogawa H, Dwinell MB et al.: Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J. Biol. Chem. 278(10), 8508-8515 (2003).
27. Ning Y, Manegold PC, Hong YK et al.: Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int. J. Cancer (2010) (Epub ahead of print).
28. Rubie C, Frick VO, Pfeil S et al.: Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer. World J. Gastroenterol. 13(37), 4996-5002 (2007).
29. Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19(13), 3159-3167 (2000).
30. Berlin J, Posey J, Tchekmedyian S et al.: Panitumumab with irinotecan/ leucovorin/5-fuorouracil for frst-line treatment of metastatic colorectal cancer. Clin. Colorectal Cancer 6(6), 427-432 (2007). (Pubitemid 46658516)
31. Van Cutsem E, Kohne CH, Hitre E et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408-1417 (2009).
32. Niknami M, Patel M, Witting PK, Dong Q: Molecules in focus: cytosolic phospholipase A2-a. Int. J. Biochem. Cell Biol. 41(5), 994-997 (2009).
33. Wang D, Dubois RN: Eicosanoids and cancer. Nat. Rev. Cancer 10(3), 181-193 (2010).
34. Lim SC, Cho H, Lee TB et al.: Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer. Yonsei Med. J. 51(5), 692-699 (2010).
35. Campbell-Thompson M, Lynch IJ, Bhardwaj B: Expression of estrogen receptor (ER) subtypes and ERb isoforms in colon cancer. Cancer Res. 61(2), 632-640 (2001).
36. Wada-Hiraike O, Imamov O, Hiraike H et al.: Role of estrogen receptor b in colonic epithelium. Proc. Natl Acad. Sci. USA 103(8), 2959-2964 (2006).
37. Xie LQ, Yu JP, Luo HS: Expression of estrogen receptor b in human colorectal cancer. World J. Gastroenterol. 10(2), 214-217 (2004).
38. Konstantinopoulos PA, Kominea A, Vandoros G et al.: Oestrogen receptor b (ERb) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur. J. Cancer 39(9), 1251-1258 (2003).
39. Martineti V, Picariello L, Tognarini I et al.: ERb is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocr. Relat. Cancer 12(2), 455-469 (2005).
40. Press OA, Zhang W, Gordon MA et al.: Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res. 68(8), 3037-3042 (2008).
41. DeCosse J J, Ngoi SS, Jacobson JS, Cennerazzo WJ: Gender and colorectal cancer. Eur. J. Cancer Prev. 2(2), 105-115 (1993).
42. Gao RN, Neutel CI, Wai E: Gender differences in colorectal cancer incidence, mortality, hospitalizations and surgical procedures in Canada. J. Public Health (Oxf.) 30(2), 194-201 (2008).
43. Zhang W, Park DJ, Lu B et al.: Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin. Cancer Res. 11, 600-605 (2005).
44. Heinzen EL, Yoon W, Tate SK et al.: Nova2 interacts with a cis-acting polymorphism to infuence the proportions of drug-responsive splice variants of SCN1A. Am. J. Hum. Genet. 80(5), 876-883 (2007).
45. Weale ME, Depondt C, Macdonald SJ et al.: Selection and evaluation of tagging SNPs in the neuronal-sodium-channel gene SCN1A: implications for linkage-disequilibrium gene mapping. Am. J. Hum. Genet. 73(3), 551-565 (2003).
46. Breiman L, Friedman JH, Olshen RA, Stone CJ: Classifcation and Regression Trees. Chapman & Hall, (Wadsworth, Inc), NY, USA (1984).
47. Yin J, Li J, Ma Y, Guo L, Wang H, Vogel U: The DNA repair gene ERCC2/ XPD polymorphism Arg 156Arg (A22541C) and risk of lung cancer in a Chinese population. Cancer Lett. 223(2), 219-226 (2005).
48. Wu W, Zhang W, Qiao R et al.: Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population. Clin. Cancer Res. 15(11), 3889-3895 (2009).
49. Schabath MB, Delclos GL, Grossman HB et al.: Polymorphisms in XPD exons 10 and 23 and bladder cancer risk. Cancer Epidemiol. Biomarkers Prev. 14(4), 878-884 (2005).
50. Lin J, Pu X, Wang W, Matin S et al.: Case-control ana lysis of nucleotide excision repair pathway and the risk of renal cell carcinoma. Carcinogenesis 29(11), 2112-2119 (2008).
51. Tate SK, Depondt C, Sisodiya SM et al.: Genetic predictors of the maximum doses patients receive during clinical use of the antiepileptic drugs carbamazepine and phenytoin. Proc. Natl Acad. Sci. USA 102(15), 5507-5512 (2005).
52. Lossin C: A catalog of SCN1A variants. Brain Dev. 31(2), 114-130 (2009).
53. Lakhan R, Kumari R, Misra UK, Kalita J, Pradhan S, Mittal B: Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. Br. J. Clin. Pharmacol. 68(2), 214-220 (2009).
54. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C: The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur. J. Pharmacol. 406(1), 25-32 (2000).
55. + channel expression to cell behaviors involved in the metastatic cascade in rat prostate cancer: II. Secretory membrane activity J. Cell Physiol. 195(3), 461-469 (2003).
56. Buerger H, Gebhardt F, Schmidt H et al.: Length and loss of heterozygosity of an intron 1 polymorphic sequence of EGFR is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res. 60(4), 854-857 (2000).
57. Gebhardt F, Zanker KS, Brandt B: Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J. Biol. Chem. 274(19), 13176-13180 (1999).
58. Hemming AW, Davis NL, Kluftinger A et al.: Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J. Surg. Oncol. 51(3), 147-152 (1992).
59. Barbosa NR, Junqueira RM, Vallada HP, Gattaz WF: Association between BanI genotype and increased phospholipase A2 activity in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 257(6), 340-343 (2007).
60. Tay A, Simon JS, Squire J, Hamel K, Jacob HJ, Skorecki K: Cytosolic phospholipase A2 gene in human and rat: chromosomal localization and polymorphic markers. Genomics 26(1), 138-141 (1995).
61. Thomas W, Coen N, Faherty S, Flatharta CO, Harvey BJ: Estrogen induces phospholipase A2 activation through ERK1/2 to mobilize intracellular calcium in MCF-7 cells. Steroids 71(3), 256-265 (2006).
62. Links phospholipase A2 with gender. Slattery ML, Sweeney C, Murtaugh M et al.: Associations between ERa, ERb, and AR genotypes and colon and rectal cancer. Cancer Epidemiol. Biomarkers Prev. 14(12), 2936-2942 (2005).
63. Press OA, Zhang W, Gordon MA et al.: Gender-related survival differences associated with polymorphic variants of estrogen receptor-b (ERb) in patients with metastatic colon cancer. Pharmacogenomics J. (2010) (Epub ahead of print).
64. Ugai K, Nishimura K, Fukino K, Nakamura T, Ueno K: Functional ana lysis of transcriptional activity of cytosine and adenine (CA) repeats polymorphism in the estrogen receptor b gene. J. Toxicol. Sci. 33(2), 237-240 (2008).